LAV — Full Portfolio

Legend Biotech is a biotechnology company.

BiotechSomerset, US

Yuan Xu, Ph.D.(Executive Officer, Director)Ying Huang, Ph.D.(Executive Officer)Fangliang Zhang, Ph.D.(Director)Ye Wang, M.S.(Director)

Co-investorsLilly Asia Ventures

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)Udayan Guha(Executive Officer)Steven P. Cobourn(Executive Officer)Sourav Kundu(Executive Officer)Kevin Shaw(Executive Officer)

Co-investorsBay City CapitalCanaan PartnersLilly Asia VenturesPfizer Venture InvestmentsQuan CapitalSofinnova Ventures+2 more

Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.

BiotechHealthtech

Praveen Tipirneni(Chief Executive Officer)Liangsu Wang(Chief Scientific Officer)Zhong Liu(Chief Technology Officer)Aaron Pelta(Chief Business Officer)Colm White(Chief Program Officer)

Co-investorsAtlas VentureJanus Henderson InvestorsvenBio Partners

San Diego, US

Board seatJudith Li· per SEC Form D · $200M raise · filed Aug 2023

Co-investorsAscenta CapitalLilly Asia VenturesSilverArc PrivateTCG Crossover

San Diego, US

Board seatJudith Li· per SEC Form D · $75M raise · filed Sep 2025

Co-investorsDecheng CapitalLilly Asia Ventures

Co-investorsLilly Asia VenturesQiming Venture Partners

Co-investorsLilly Asia Ventures

Airdoc offers a home-use eye-care device called Yingtu PBM that uses low-intensity photobiomodulation (PBM) light therapy to help slow myopia progression in children and adolescents.

Digital HealthHardwareHealthtech

Co-investorsLilly Asia Ventures

Alebund Pharmaceuticals develops innovative treatments for kidney diseases, with a pipeline covering chronic kidney conditions such as diabetic nephropathy, IgA nephropathy, FSGS, and ADPKD, as well as end-stage renal disease complications like hyperphosphatemia and anemia.

BiotechDigital HealthShanghai, CN

Co-investorsLilly Asia VenturesQuan Capital3E Bioventures CapitalSherpa Healthcare Partners

Ansun Biopharma develops therapeutics aimed at treating respiratory viral infections that lack existing treatment options.

BiotechSan Diego, US

RONALD MOSS(Executive Officer)MARK ATTEBURY(Executive Officer)MIKAEL HAVLUCIYAN(Executive Officer)

BoardALLEN CHAO(Director)MICHAEL CHANG(Director)NANCY CHANG(Director)

Co-investorsLilly Asia Ventures

Co-investorsAisling CapitalLilly Asia VenturesQuan Capital

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Zhengbin (Bing) Yao(Executive Officer, Director)Brent Rice(Chief Commercial Officer)

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHongShan Capital GroupLilly Asia VenturesOrbiMed+2 more

Co-investorsLilly Asia Ventures

BiotechHealthtechMedical DevicesWaltham, US

David F. Muller(Executive Officer, Director)Brian J. Roberts(Executive Officer)Rhonda J. Bracey(Executive Officer)

BoardJason Hong(Director)Jeff Dykan(Director)inAnthony Natale(Director)in

Co-investorsAPERTURE Venture PartnersLilly Asia VenturesSCP Vitalife PartnersThird Point VenturesHealthQuest CapitalOrbiMed

Betta Pharmaceuticals is a Chinese pharmaceutical company focused on developing and commercializing innovative drugs, including cancer therapies such as Icotinib (Conmana).

BiotechHealthtech

Co-investorsLilly Asia Ventures

Burning Rock Dx is a diagnostics company that applies next-generation sequencing (NGS) technology to precision oncology, offering NGS-based assays for tissue and blood samples along with an in-house database.

BiotechDigital HealthMedical Devices

Co-investorsLilly Asia Ventures

BiotechCambridge, US

Praveen Tipirneni(Executive Officer, Director)

BoardMichelle Doig(Director)inAaron Royston(Director)Michael Gladstone(Director)inXiaodi Su(Director)

Co-investorsAtlas VentureBain Capital Life SciencesJanus Henderson InvestorsOmega FundsvenBio Global StrategicvenBio Partners+1 more

CanSinoBIO is a biopharmaceutical company that researches, manufactures, and commercializes human vaccines for the prevention and treatment of infectious diseases.

BiotechHealthtech

Co-investorsLilly Asia Ventures

Co-investorsLilly Asia Ventures

Co-investorsLilly Asia Ventures

Xian-ping LU(Founder)in

Co-investorsLilly Asia VenturesLYZZ CapitalVertex Ventures China

Connect Biopharm develops next-generation therapeutics for inflammatory diseases.

Biotech

Co-investorsLilly Asia VenturesQiming Venture Partners

CorrectSequence Therapeutics (正序生物) develops precision therapies based on its proprietary base editing platform, targeting genetic diseases such as thalassemia and sickle cell disease.

BiotechDeep TechHealthtechShanghai, CN

牟晓盾(CEO)

Co-investorsLilly Asia Ventures

Crown Bioscience is a contract research organization (CRO) providing preclinical and translational research services in oncology and immuno-oncology drug discovery, including a large library of cancer models such as PDX, cell line derived xenografts, syngeneic, and in vitro models.

BiotechHealthtech

Co-investorsAcorn Pacific VenturesGRC SinogreenLilly Asia VenturesQiming Venture Partners

Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.

BiotechDigital Health

Co-investorsLilly Asia VenturesMPM BioImpactSchooner CapitalTaiho Ventures, LLC

EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform.

BiotechDeep TechHealthtech

Co-investorsLilly Asia VenturesWI Harper Group

Co-investorsLilly Asia Ventures

Co-investorsLilly Asia Ventures

Skyline Therapeutics develops gene therapies using an adeno-associated virus (AAV) platform that combines capsid discovery, vector engineering, process development, and GMP manufacturing.

BiotechHealthtech

Co-investorsF-Prime CapitalLilly Asia Ventures

Geneseeq develops next-generation sequencing (NGS) based genetic tests and in-vitro diagnostic products for cancer patients, using gene profiling to guide targeted drug selection, indicate drug resistance mechanisms, and monitor post-surgical recurrence.

AI & Machine LearningBiotechDigital HealthNanjing, CN

Co-investorsLilly Asia Ventures

Gracell develops CAR-T cell therapies aimed at delivering fast, deep, and durable responses for patients with cancer and autoimmune disease.

BiotechHealthtech

Co-investorsLilly Asia VenturesOrbiMed

Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.

BiotechDeep TechHealthtechSan Carlos, US

Wayne(CEO)Rachel(VP of Operations)

Co-investorsBay City CapitalGV (Google Ventures)Lilly Asia Ventures

Beijing Huamai Taike Medical Instrument develops, manufactures, and sells medical devices for treating vascular diseases, covering the aortic, peripheral, coronary, and neurointervention/access areas.

HardwareHealthtechMedical DevicesBeijing, CN

Co-investorsLilly Asia Ventures

Co-investorsDecheng CapitalLilly Asia Ventures

Inhibrx develops protein therapeutics, using target biology and protein engineering to create therapeutic candidates in clinical trials for conditions including sarcoma and head and neck cancer.

BiotechLa Jolla, US

Mark Lappe(Executive Officer, Director)Brendan Eckelman(Director)Doug Forsyth(Director)Jon Faiz Kayyem(Director)Margery Fischbein(Director)

BoardJudith Li(Director)

Co-investorsLilly Asia VenturesRA CapitalOxford Finance LLC

Co-investorsF-Prime CapitalLilly Asia VenturesLegend Capital

Insilico Medicine applies computational and AI-based modeling to drug design and problems such as protein folding for pharmaceutical research and development.

AI & Machine LearningBiotechHealthtechHong Kong

Alex Zavoronkov(Director)Alex Zhavoronkov(Founder & CEO)

BoardNisa Leung(Director)Lennart Lee(Director)James Mellon(Director)

Co-investorsB Capital GroupB4 CapitalBOLD LongevityF-Prime CapitalGestio CapitalLilly Asia Ventures+5 more

InventisBio (益方生物) is a biopharmaceutical company that develops small-molecule drugs, including candidates targeting KRAS G12C for lung and pancreatic cancer and treatments for moderate-to-severe plaque psoriasis.

BiotechHealthtechShanghai, CN

Xing Dai(Founder)in

Co-investorsLilly Asia VenturesOrbiMedQiming Venture Partners

Ionova Bio is a biopharmaceutical company that discovers and develops next-generation cancer therapies with clinical benefit for patients globally.

BiotechHealthtechShenzhen, CN

Co-investorsLilly Asia Ventures

Jacobio Pharmaceuticals is a biotech company that develops first-in-class oncology drugs using its allosteric drug discovery platform and iADC platform, targeting difficult-to-drug targets across validated tumor signaling pathways.

BiotechDeep TechHealthtech

Co-investorsLilly Asia VenturesQiming Venture Partners

Co-investorsLilly Asia Ventures

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)FRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)JAMES GILBERT(Director)

BoardALAN L. CRANE(Director)

Co-investorsAlpha Wave GlobalARCH Venture PartnersFlagship PioneeringLilly Asia VenturesBaillie GiffordPolaris Partners

Lupeng Bio is a biotechnology company focused on the design and development of new anti-tumor (oncology) drugs.

BiotechHealthtech

Co-investorsLilly Asia VenturesOrbiMed

Lynk Pharmaceuticals is a clinical-stage drug company developing small-molecule therapies for autoimmune and inflammatory diseases, targeting JAK-STAT and TYK2 signaling pathways and using targeted protein degradation to create oral alternatives to biologics.

AI & Machine LearningBiotechHealthtech

Co-investorsDecheng CapitalLilly Asia Ventures

Co-investorsLilly Asia Ventures

Co-investorsB Capital GroupB4 CapitalF-Prime CapitalLilly Asia VenturesMarathon Venture Partners

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in

Co-investorsage1EcoR1 CapitalLilly Asia VenturesNew Enterprise Associates (NEA)Vivo CapitalARCH Venture Partners+2 more

MicroTech Medical produces the Equil patch insulin pump, a tubeless wearable pump for people managing diabetes, and references the Aidex continuous glucose monitoring system (CGMS) for real-time glucose tracking.

Digital HealthHardwareMedical Devices

Co-investorsLilly Asia VenturesLYZZ CapitalQiming Venture Partners

Milliin (迈淩) develops hemodialysis equipment and related products, including dialysis machines, dialysis water treatment systems, centralized concentrate supply systems, and dialysis dry powder.

HardwareHealthtechMedical Devices

Co-investorsLilly Asia Ventures

Co-investorsAcorn Pacific VenturesLilly Asia VenturesLegend Capital

NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.

BiotechHealthtechWilmington, CN

Yan Lou(Founder)Gary Yeung(Director)Ting Jia(Director)Hong (Kelsey) Chen(Chief Financial Officer)Zhenhai Gao(President, CEO, and Secretary)Roderick Wong(Director)

Co-investorsEcoR1 CapitalLilly Asia VenturesRA CapitalSamsara BioCapitalThe Innovation SpaceLogos

Co-investorsLilly Asia VenturesQiming Venture Partners

BiotechCampbell, US

Amr Salahieh(Executive Officer, Director)Casey Gordon(Director)Mariam Maghribi(Executive Officer)

Co-investorsLilly Asia Ventures

Perfuse Therapeutics is a biotechnology company developing a therapy to improve blood flow to the retina, targeting ocular diseases such as glaucoma and diabetic retinopathy.

BiotechMedical DevicesSan Francisco, US

BoardChristy Shaffer(Director)Chau Khuong(Director)inSevgi Gurkan(Executive Officer, Director, Promoter)in

Co-investorsAccess BiotechnologyCatalio Capital Management, LPHatteras Venture PartnersLilly Asia VenturesOrbiMedHatteras

Co-investorsLilly Asia VenturesLegend Capital

Co-investorsB Capital GroupB4 CapitalLilly Asia VenturesLYFE CapitalNextech InvestRA Capital

Hangzhou-based gene-editing biotech developing immune-privileged cell therapies and xenogeneic organs for transplant and cancer.

Co-investorsAlta PartnersARCH Venture PartnersSequoia Capital

Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.

BiotechDeep TechHardwareHealthtechCambridge, US

Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)

BoardYuh-Geng Tsay(Director)Victor Tong(Director)Thomas Grogan(Director)

Co-investorsLilly Asia VenturesLilly VenturesVivo Capital

Regor is a drug discovery company that uses a computational platform (rCARD) to identify and optimize preclinical small-molecule candidates in metabolism, oncology, and immunology, which it licenses to pharmaceutical companies for clinical development.

AI & Machine LearningBiotechDeep TechShanghai, CN

Xiayang Qiu(Founder)in

Co-investorsLilly Asia VenturesVertex Ventures

RemeGen is a biopharmaceutical company that develops and commercializes novel antibody and fusion protein therapeutics, including telitacicept (a BLyS/APRIL dual-target fusion protein) and disitamab vedotin, for conditions such as autoimmune diseases and cancers.

BiotechHealthtechYantai, CN

王威东(Co-founder)房健民(Co-founder)

Co-investorsLilly Asia Ventures

Rona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH.

BiotechLongevityShanghai, CN

Jinyu Huang(Chief Executive Officer, Founder)Stella Shi(Founder & Chief Executive Officer, Chair of the Board)Stella (Yibin) Shi(Founder)

Co-investorsLilly Asia Ventures

Singleron Biotechnologies develops single-cell and single-nucleus sequencing kits and solutions for transcriptome analysis of biological samples.

BiotechMedical DevicesCologne, DE

Co-investorsARCH Venture PartnersLilly Asia VenturesMSA Capital

Co-investorsLilly Asia Ventures

Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Jeffrey Bluestone(Executive Officer, Director, Promoter)

BoardFan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)

Co-investors8VCARCH Venture PartnersFrazier Life SciencesJDRF T1D FundLifeforce CapitalLilly Asia Ventures+1 more

Sperogenix (曙方医药) is a biopharmaceutical company focused on developing and commercializing drugs for genetic rare diseases in China, covering areas such as neuromuscular disorders, neurodevelopmental disorders, inherited metabolic diseases, and blood disorders.

BiotechHealthtech

Co-investorsLilly Asia Ventures

Co-investorsLilly Asia Ventures

Co-investorsLilly Asia Ventures

Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.

BiotechHealthtechBrisbane, US

Stephen Brady(Director)Matthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)Thomas Woiwode(Director)Geoffrey Nichol(Director)Thomas W. Dubensky(Executive Officer, Director)

Co-investorsF-Prime CapitalLilly Asia VenturesNew Enterprise Associates (NEA)Quan CapitalRoche Venture Fund

Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program.

BiotechHealthtechFoster City, US

Mark Vignola, Ph.D.(Executive Officer)Bryan Yoon(Executive Officer)Senthil Sundaram(Director, Executive Officer)Weidong Zhong, Ph.D.(Executive Officer, Director)Jill Quigley(Director)David Fellows(Director)

Co-investorsDecheng CapitalLilly Asia VenturesVivo Capital

BiotechPhiladelphia, US

Anne Chew(Director and President)

BoardKevin Mahoney(Director)

Co-investorsAndreessen HorowitzKleiner PerkinsLilly Asia VenturesMilitia Hill VenturesGilead Sciences

Co-investorsForesite CapitalLilly Asia VenturesNextech InvestSv Tech Ventures, Inc.

Co-investorsLilly Asia Ventures

Co-investorsLilly Asia VenturesPfizer Venture Investments

Co-investorsLilly Asia Ventures

Co-investorsHighlight CapitalLilly Asia Ventures

Innovative biopharma company focused on cancer and immune disease therapies (SHSE: 688192).

Co-investorsHongShan Capital GroupLilly Asia Ventures